Not a good buy right now: near-term technicals are bearish (MACD worsening, price below pivot), and options flow is overwhelmingly put-skewed, which typically signals downside/hedging pressure.
With no Intellectia buy signals today and pattern-based stats pointing to more weakness over the next week, this is an “avoid/sell now” setup for an impatient investor.
Long-term upside exists (RBC Outperform with a $40 target; hedge funds accumulating), but the current tape/derivatives sentiment argues against buying immediately ahead of clearer stabilization.
Trend/Momentum: Bearish momentum building—MACD histogram is -0.171 (below zero) and negatively expanding, implying downside momentum is strengthening.
RSI: RSI(6) ~38, leaning weak (not deeply oversold), leaving room for further downside before a typical “snap-back” level.
Moving averages: Converging MAs suggest consolidation after weakness rather than a confirmed reversal.
Key levels: Pivot 16.121 (price below pivot = bearish bias). Immediate support S1 15.208; if that breaks, next support S2 14.644. Resistance levels: R1 17.034 then R2 17.598.
Quant/pattern read: Similar-pattern stats imply ~70% chance of -0.82% next day and -3.03% next week (near-term bias down), with a modest +1.67% one-month projection.
Liquidity/Activity: Total volume 86 vs 30D average (93.48%)—activity is near typical, so the put-skew isn’t just a one-off spike.
Volatility: 30D IV ~126.56% vs historical vol ~105.98% (elevated), but IV percentile ~22 and IV rank ~27 suggest IV is not extremely high versus its own recent history (room for IV expansion into catalysts like earnings).
Technical Summary
Sell
4
Buy
8
Positive Catalysts
Event catalyst: Upcoming earnings (QDEC
on 2026-03-02 pre-market could re-rate the stock if updates on pipeline/clinical progress are strong.
Neutral/Negative Catalysts
Derivatives sentiment is strongly bearish/defensive (extreme put-dominant volume), which often aligns with near-term downside risk.
Technical momentum is deteriorating (MACD negative and expanding), and price is below the 16.121 pivot with nearby support at 15.208 vulnerable.
No supportive near-term news flow in the past week; absent a fresh catalyst, bearish tape can persist.
Pre-revenue biotech risk profile: ongoing losses and reliance on clinical/financing milestones can pressure shares, especially into key dates.
Financial Performance
Latest reported quarter: 2025/Q3.
Revenue: 0 (no commercial revenue yet).
Net income: -$14.02M, improving ~15.73% YoY (loss narrowing, but still meaningfully negative).
EPS: -0.23 (still loss-making).
Overall: improving loss profile, but fundamentals are still primarily pipeline/clinical-execution driven rather than operating-growth driven.
Growth
Profitability
Efficiency
Analyst Ratings and Price Target Trends
Recent change: On 2026-01-23, RBC Capital raised PT to $40 from $33 and maintained Outperform.
Wall Street pros: Clear long-term upside narrative (GH001 potential; payer/doctor discussions cited) and supportive institutional accumulation.
Wall Street cons: Current market/derivatives positioning is risk-off, and without near-term proof points, the stock can trade technically weak despite bullish long-term targets.
Influential/insider/political activity: Insiders neutral recently; no recent Congress trading data available.
Wall Street analysts forecast GHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GHRS is 28.6 USD with a low forecast of 19 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Analyst Rating
Wall Street analysts forecast GHRS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GHRS is 28.6 USD with a low forecast of 19 USD and a high forecast of 35 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
6 Buy
0 Hold
0 Sell
Strong Buy
Current: 13.660
Low
19
Averages
28.6
High
35
Current: 13.660
Low
19
Averages
28.6
High
35
RBC Capital
Outperform
maintain
$33 -> $40
AI Analysis
2026-01-23
Reason
RBC Capital
Price Target
$33 -> $40
AI Analysis
2026-01-23
maintain
Outperform
Reason
RBC Capital raised the firm's price target on GH Research to $40 from $33 and keeps an Outperform rating on the shares. Following the firm's Psychedelics Symposium and discussions with the management, payers, and doctors, RBC is increasingly optimistic on GH's long- term sales opportunity, with GH001, the analyst tells investors in a research note.
Cantor Fitzgerald
initiated
$25
2025-06-04
Reason
Cantor Fitzgerald
Price Target
$25
2025-06-04
initiated
Reason
Cantor Fitzgerald assumed coverage of GH Research with an Overweight rating and $25 price target. Data generated for psychedelics across a number of mental health disorders have been "transformational," and the unmet need is "enormous" and growing, the analyst tells investors in a research note. The firm says sees the psychedelic total addressable market ultimately reaching $50B per year, which would be roughly 1M-1.5M patients treated per year, still only modest penetration, and believes there is room for plenty of successful options and companies offering psilocybin and novel synthetic products.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for GHRS
